Brief: Selecta Biosciences And Genovis Enter Exclusive License Agreement To Advance Next-Generation IgG Protease

Genovis AB

21/10/2021 13:33

Oct 21 (Reuters) - Genovis AB  GENOb.ST :
    * SELECTA BIOSCIENCES AND GENOVIS ENTER EXCLUSIVE LICENSE
AGREEMENT TO ADVANCE NEXT-GENERATION IGG PROTEASE IN GENE
THERAPY AND AUTOIMMUNE DISEASE
    * SELECTA BIOSCIENCES INC - OBTAINS FROM GENOVIS EXCLUSIVE
WORLDWIDE RIGHTS TO XORK, A DIFFERENTIATED IGG PROTEASE
    * SELECTA BIOSCIENCES INC - PROVIDED GENOVIS WITH AN UPFRONT
PAYMENT FOR AN EXCLUSIVE LICENSE TO XORK FOR ALL THERAPEUTIC
USES IN HUMANS
    * SELECTA BIOSCIENCES INC - GENOVIS RETAINS RIGHTS TO
RESEARCH,
PRECLINICAL, DIAGNOSTIC, AND OTHER POTENTIAL NON-THERAPEUTIC
APPLICATIONS OF XORK
    * SELECTA BIOSCIENCES - GENOVIS ELIGIBLE TO EARN
DEVELOPMENT,SALES-BASED MILESTONES, AS WELL AS TIERED ROYALTIES
ON WORLDWIDE SALES IN LOW DOUBLE DIGITS

Source text for Eikon:  ID:nGNX3yffDs 
Further company coverage:  GENOb.ST 

 ((Reuters.Briefs@thomsonreuters.com;))